“解郁兴阳汤”治疗抗精神病药物所致勃起功能障碍的临床研究

注册号:

Registration number:

ITMCTR2200005913

最近更新日期:

Date of Last Refreshed on:

2022-04-26

注册时间:

Date of Registration:

2022-04-26

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

“解郁兴阳汤”治疗抗精神病药物所致勃起功能障碍的临床研究

Public title:

Clinical Study of ''Jieyu Xingyang decoction'' in treating erectile dysfunction caused by antipsychotic

注册题目简写:

English Acronym:

研究课题的正式科学名称:

“解郁兴阳汤”治疗抗精神病药物所致勃起功能障碍的临床研究

Scientific title:

Clinical Study of ''Jieyu Xingyang decoction'' in treating erectile dysfunction caused by antipsychotic

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200059181 ; ChiMCTR2200005913

申请注册联系人:

王又天

研究负责人:

于林

Applicant:

Wang Youtian

Study leader:

Yu Lin

申请注册联系人电话:

Applicant telephone:

13113570857

研究负责人电话:

Study leader's telephone:

18998321536

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wang13113570857@163.com

研究负责人电子邮件:

Study leader's E-mail:

yulinfimmu@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

广东省广州市荔湾区芳村明心路36号

研究负责人通讯地址:

广东省广州市荔湾区芳村明心路36号

Applicant address:

36 Mingxin Road, Liwan District, Guangzhou, Guangdong Province

Study leader's address:

36 Mingxin Road, Liwan District, Guangzhou, Guangdong Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广州医科大学附属脑科医院

Applicant's institution:

Affiliated Brain Hospital of Guangzhou Medical University

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

(2021)第(021)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

广州医科大学附属脑科医院伦理委员会

Name of the ethic committee:

IRB, The Affiliated Brain Hospital of Guangzhou Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2021/3/18 0:00:00

伦理委员会联系人:

刘小燕

Contact Name of the ethic committee:

Liu Xiaoyan

伦理委员会联系地址:

广东省广州市荔湾区芳村明心路36号

Contact Address of the ethic committee:

36 Mingxin Road, Liwan District, Guangzhou, Guangdong Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

020-81268229

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广州医科大学附属脑科医院

Primary sponsor:

Affiliated Brain Hospital of Guangzhou Medical University

研究实施负责(组长)单位地址:

广东省广州市荔湾区芳村明心路36号

Primary sponsor's address:

36 Mingxin Road, Liwan District, Guangzhou, Guangdong Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广州医科大学附属脑科医院

具体地址:

广东省广州市荔湾区芳村明心路36号

Institution
hospital:

Affiliated Brain Hospital of Guangzhou Medical University

Address:

36 Mingxin Road, Liwan District, Guangzhou, Guangdong Province

国家:

省(直辖市):

市(区县):

Country:

Province:

City:

单位(医院):

具体地址:

Institution
hospital:

Address:

经费或物资来源:

广州医科大学附属脑科医院院内配套经费

Source(s) of funding:

Hospital supporting funds of Affiliated Brain Hospital of Guangzhou Medical University

研究疾病:

抗精神病药物所致勃起功能障碍

研究疾病代码:

Target disease:

Erectile dysfunction due to antipsychotics

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

III期临床试验

Phase III clinical trial

研究目的:

男性阴茎勃起功能障碍是常见的抗精神病药物副作用。服用抗精神病药物的患者中,高达48%~75%的患者出现性功能障碍。药物相关的勃起功能障碍中,大约有50%与抗精神病药物的使用相关。其中非典型抗精神病药物利培酮可能产生患者性欲降低或勃起功能障碍。ED的发生伴随着患者焦虑情绪的产生,容易影响服药依从性,降低患者生活质量,增加家庭与社会负担。 在本课题预实验结果中显示,催产素参与影响服用抗精神病患者的勃起功能。催产素参与多种大脑活动,参与男性勃起功能。NO是重要的阴茎勃起能神经递质,目前研究表明cAMP、cGMP对NO信号影响明显,而催产素通路可能与NO调节勃起功能相关。中医药对于ED的治疗由来已久。“疏肝气、温肾阳”的治疗理念符合APDs所致ED肝郁肾虚型患者,并且临床中取得一定的疗效。基于此,本研究以APDs所致肝郁肾虚型ED患者为研究对象,利用“解郁兴阳汤”作为治疗手段,通过临床观察比较采用“疏肝气、温肾阳”的解郁兴阳汤治疗前后患者临床疗效与NPT、IIEF-5、CALM以及NO等指标。探讨“疏肝气、温肾阳”的解郁兴阳汤与下丘脑催产素通路的关联性,以及催产素通路调节CALM的相关机制,为抗精神病药物所致肝郁肾虚型阳痿机制提供新的治疗方向。

Objectives of Study:

Erectile dysfunction in men is a common antipsychotic side effect. Sexual dysfunction occurs in 48% to 75% of patients taking antipsychotics. About 50% of drug-related erectile dysfunction is related to the use of antipsychotic drugs. Among them, the atypical antipsychotic risperidone may produce decreased libido or erectile dysfunction in patients. The occurrence of ED is accompanied by the generation of anxiety in patients, which can easily affect medication compliance, reduce the quality of life of patients, and increase the burden on families and society. In the preliminary experimental results of this subject, it is shown that oxytocin is involved in affecting the erectile function of patients taking antipsychotics. Oxytocin is involved in a variety of brain activities and is involved in male erectile function. NO is an important penile erectile neurotransmitter. Current studies have shown that cAMP and cGMP have a significant effect on NO signaling, and the oxytocin pathway may be related to NO regulation of erectile function. Traditional Chinese medicine has a long history in the treatment of ED. The treatment concept of "soothing liver qi and warming kidney yang" is in line with the ED patients with liver stagnation and kidney deficiency caused by APDs, and has achieved certain curative effects in clinical practice. Based on this, this study took APDs-induced ED patients with liver stagnation and kidney deficiency as the research object, using "Jieyu Xingyang Decoction" as a treatment method, and through clinical observation to compare the clinical symptoms of patients before and after treatment with "Jieyu Xingyang Decoction" of "soothing liver qi and warming kidney yang". Efficacy and NPT, IIEF-5, CALM and NO indicators. To explore the relationship between Jieyu Xingyang Decoction "soothing liver qi and warming kidney yang" and hypothalamic oxytocin pathway, as well as the related mechanism of oxytocin pathway regulating CALM, so as to provide a new treatment direction for the mechanism of liver stagnation and kidney deficiency type impotence caused by antipsychotic drugs .

药物成份或治疗方案详述:

解郁兴阳汤方剂组成:柴胡15g、白芍15g、枳实15g、炙甘草15g、淫羊藿10g、巴戟天10g、生龙骨30g、生牡蛎30g。两组在接受原有抗精神病药物利培酮系统治疗的基础上,中药组给予“解郁兴阳汤”中药配方颗粒治疗;对照组予安慰剂干预(“解郁兴阳汤”中药配方颗粒及安慰剂均由广东一方制药有限公司制成包装相同,口感、气味、重量相近的中药颗粒),用法:早晚各1次,每次1盒,连续干预 4 周。

Description for medicine or protocol of treatment in detail:

纳入标准:

纳入标准 (1)男性,年龄在22至50周岁,且有固定性伴侣和规律性生活; (2)符合精神障碍诊断与统计手册(第五版)DSM-V中的精神分裂症诊断标准; 且满足DSM-V临床定式访谈(SCID)精神分裂症的结果。 (3)IIEF-5评分得分≤21分; (4)近2周内连续服用利培酮;且近一周内未使用过治疗勃起功能障碍的药物,或使用过此类药物,已停药7天以上者; (5)符合《勃起功能障碍中西医结合诊疗指南(试行版)》中关于阳痿证型为肝郁肾虚的诊断标准; (6)无语言及听力障碍; (7)愿意接受为期28天中药治疗者,受试者知情,并自愿签署知情同意书; 如以上任何一个答案为“否”,此受试者不能参加。

Inclusion criteria

Inclusion criteria (1) Male, aged 22 to 50 years old, with a regular sexual partner and regular sexual life; (2) Meet the diagnostic criteria for schizophrenia in the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) DSM-V; And meet the DSM-V clinical stereotyped interview (SCID) results of schizophrenia. (3) IIEF-5 score ≤ 21 points; (4) Those who have taken risperidone continuously within the past 2 weeks; and have not used drugs for erectile dysfunction in the past week, or have used such drugs and have been discontinued for more than 7 days; (5) Meet the diagnostic criteria for erectile dysfunction syndrome of liver stagnation and kidney deficiency in the Guidelines for the Diagnosis and Treatment of Erectile Dysfunction (Trial Version); (6) No language and hearing impairment; (7) Those who are willing to accept traditional Chinese medicine treatment for 28 days, the subjects are informed, and voluntarily sign the informed consent; If the answer to any of the above is "No", the subject cannot participate.

排除标准:

排除标准 (1)既往精神病史: ①不能除外其它器质性或药物引起的继发性精神疾病; ②有严重自伤、自杀倾向神障碍病史; ③有酒精或其它物质依赖或滥用证据者; ④有精神发育迟滞或智力障碍患者。 ⑤因兴奋、冲动伤人、言行紊乱等不配合的患者。 (2)外生殖器畸形及外伤者; (3)其它躯体疾病史: ①手术后一年康复期内;②一年内有过严重躯体疾病者,如胃溃疡、慢性腹泻等胃肠道疾病,严重心、肺、 肝胆、肾等疾病的患者; ③有如癫痫等严重神经系统疾病患者; ④有脑外伤史或器质性疾病等。 (4)不能坚持配合治疗和随访者。 如以上任何一个答案为“是”,此受试者不能参加。

Exclusion criteria:

Exclusion criteria (1) Past history of mental illness: ① Other organic or drug-induced secondary mental illnesses cannot be excluded; ② There is a history of severe self-injury, suicidal tendencies and mental disorder; ③ Those who have evidence of alcohol or other substance dependence or abuse; ④ Patients with mental retardation or intellectual disability. ⑤ Patients who do not cooperate due to excitement, impulsive injury, disorder of words and deeds, etc. (2) External genital deformity and trauma; (3) History of other physical diseases: ① One-year recovery period after the operation; ② Those who have had serious physical diseases within one year, such as gastric ulcer, chronic diarrhea and other gastrointestinal diseases, severe heart, lung, Patients with liver and gallbladder, kidney and other diseases; ③ Patients with severe neurological diseases such as epilepsy; ④ There is a history of traumatic brain injury or organic diseases. (4) Those who cannot insist on cooperating with treatment and follow-up. If the answer to any of the above is "yes", the subject cannot participate.

研究实施时间:

Study execute time:

From 2020-11-01

To      2023-12-31

征募观察对象时间:

Recruiting time:

From 2022-05-30

To      2023-12-31

干预措施:

Interventions:

组别:

干预组

样本量:

35

Group:

intervention group

Sample size:

干预措施:

解郁兴阳汤

干预措施代码:

Intervention:

Jieyu Xingyang decoction

Intervention code:

组别:

对照组

样本量:

35

Group:

control group

Sample size:

干预措施:

无任何中医干预措施

干预措施代码:

Intervention:

No TCM Intervention Measures

Intervention code:

样本总量 Total sample size : 70

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广州医科大学附属脑科医院

单位级别:

三级甲等

Institution/hospital:

Affiliated Brain Hospital of Guangzhou Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

阳性和阴性症状量表

指标类型:

次要指标

Outcome:

PANSS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

夜间阴茎勃起监测

指标类型:

主要指标

Outcome:

Nocturnal Penite Tumescence

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医证候评价

指标类型:

次要指标

Outcome:

Evaluation of syndrome of TCM

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

国际勃起功能指数

指标类型:

次要指标

Outcome:

International Erectile Function Index-5

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

BDNF、NO信号通路相关分子

指标类型:

附加指标

Outcome:

BDNF,NO,et al

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

副反应量表

指标类型:

副作用指标

Outcome:

TESS

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

惊跳反射弱刺激测试

指标类型:

次要指标

Outcome:

PPI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

外周血

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

粪便

组织:

Sample Name:

faece

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 22
Min age years
最大 50
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男性

Male

随机方法(请说明由何人用什么方法产生随机序列):

采用区组随机,借助SAS统计软件PROC PLAN过程语句,给定种子数,产生随机安排。随机号以密闭不透光牛皮纸信封隐藏。

Randomization Procedure (please state who generates the random number sequence and by what method):

Using Block randomization and SAS statistical software PROC PLAN process statement, given the number of seeds, the random arrangement is generated.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No sharing

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统